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been used to condition elderly or ill patients with hematological malignancies for
allogeneic hematopoietic cell transplantation (HCT). Initial mixed donor/host chi-
merism (i.e. the coexistence of hematopoietic cells of host and donor origin) has
been observed in most patients after such transplants. Here, we describe both fac-
tors affecting engraftment kinetics in patients given a nonmyeloablative or a
reduced-intensity conditioning, and associations between peripheral blood cell sub-










conditioning regimens for allogeneic
HCT
To avoid serious regimen-related toxicities, the use
of conventional allogeneic hematopoietic cell
transplantation (HCT) has been restricted to268-960X/$ - see front matter c 2004 Elsevier Ltd. All rights rese
oi:10.1016/j.blre.2004.06.003
* Corresponding author. Tel.: +44-206-667-4470/4875; fax:
44-206-667-6124.
E-mail addresses: fbaron@fhcrc.org (F. Baron), mlittle@
hcrc.org (M.-T. Little), rstorb@fhcrc.org (R. Storb).younger and medically fit patients.1 This is unfortu-
nate since the median age at diagnosis for patients
with hematological malignancies such as acute and
chronic leukemias, lymphomas, multiple myeloma
or myelodysplastic syndromes, ranges from 65 to
70 years,2 thereby precluding the use of allogeneic
HCT for most patients with these diseases. The cur-
ative potential of allogeneic HCT has been ascribed
not only to the eradication of malignant cells by
high-dose chemotherapy and total body irradia-
tion, but also to immune-mediated graft-versus-
tumor (GVT) effects.3–5 The power of therved.
Table 1 Examples of reduced-intensity or nonmyeloablative conditioning regimens.






Diseases GVHD NRM (days after
transplant)
Outcome
Acute (grades 2–4) Chronic
MD Anderson47 Fludarabine 25 mg/m2/day (or
2-CDA 12 mg/m2)·5 days
FK506+MTX 86 (52) Hematological
malignancies
49% 68% 37% (at 100 days) 730-day OS: 28%
Melphalan 140–180 mg/m2 730-day DFS: 23%
United Kingdom48 Fludarabine 30 mg/m2/day·
5 days
CSP+/MTX 44 (41) Hematological
malignancies. 19
pts had a previous
failed transplant
3/44.1 after DLI. NR 11% (at 365 days) 360-day OS: 73%
Melphalan 140 mg/m2 360-day PFS: 71%
CAMPATH-1H 20 mg/day·
5 days
Jerusalem49 Fludarabine 30 mg/m2/day·
6 days
CSP+/MTX 24 (35) Chronic myeloid
leukemia in first
chronic phase
75%a 55% 3 pts (days 116, 499
and 726)
1725-day DFS: 85%
Busulfan (p.o.) 4 mg/kg/day·
2 days
ATG 5–10 mg/kg/day·4 days
MD Anderson50 Fludarabine 25 mg/m2/day
(or 2-CDA 12 mg/m2/day)·5
days or Fludarabine 30 mg/m2/
day·3 days
















NR 2 pts (days 59
and 205)
8/15 pts survived




Boston11 Cyclophosphamide 50 mg/kg/
day·3–4 days




NR 2 pts (days 77 and
180)
At a median follow-up of
445 days:
ATG 30 mg/kg/ day·3 days or
15 mg/kg/ day·4 days
11 pts were surviving




















































































































































































































































































































































































































































































Kinetics of engraftment following allogeneic hematopoietic cell transplantation 155lymphocyte-mediated GVT effects has led several
groups of investigators to explore the curative
potential of donor lymphocyte infusions (DLI) in pa-
tients who had relapsed with hematological malig-
nancies after allogeneic HCT.6,7 The induction of
durable remissions by DLI in a number of patients
demonstrated that GVT effects were capable of
eradicating hematological malignancies, even in
the absence of chemotherapy.
In an attempt to extend the use of allogeneic
HCT to older patients and those with comorbid con-
ditions, several groups of investigators have ex-
plored allogeneic HCT after reduced-intensity8–10
or truly nonmyeloablative conditioning regi-
mens11–14 in which the burden of tumour eradica-
tion was shifted toward GVT effects.
Examples of reduced-intensity or truly nonmy-
eloablative conditioning regimens are shown in
Table 1. Many of the regimens did not meet crite-
ria of nonmyeloablative conditioning which have
included: (1) no eradication of host hematopoi-
esis, (2) prompt endogenous hematologic recovery
(<4 weeks) without transplant and (3) presence of
mixed chimerism upon allogeneic engraftment.
Analogous to conventional regimens, reduced-
intensity regimens produce major anti-tumor ef-
fects and reduce host-versus-graft reactions. In
contrast, nonmyeloablative regimens rely on opti-
mization of pre- and post-transplant immunosup-
pression to overcome host-versus-graft reactions
and allow allogeneic engraftment, thereby setting
the stage for eradication of tumors by GVT ef-
fects. In patients with slowly progressing diseases
(e.g. chronic lymphocytic leukemia, low-grade
nonHodgkin lymphoma, or chronic myeloid leuke-
mia in first chronic phase) or with more aggressive
diseases in complete remission, a nonmyeloabla-
tive conditioning regimen might be sufficient to
achieve engraftment and cure the malignant dis-
ease. However, cytoreduction might be required
in patients with aggressive diseases, e.g. acute
leukemia, multiple myeloma, high-grade lym-
phoma, Hodgkin disease, who are not in complete
remission at the time of the transplant.
After extensive pre-clinical studies in a dog
model,15 we have developed a nonmyeloablative
conditioning regimen consisting of low-dose (2
Gy) total body irradiation (TBI)±fludarabine 30
mg/m2/days·3 days to condition elderly or ill pa-
tients with hematological malignancies for alloge-
neic HCT.12 Postgrafting immunosuppression
consisted of mycophenolate mofetil (MMF) and
cyclosporine (CSP) (Fig. 2). The clinical trials were
carried out jointly by a group of collaborators lo-
cated at the Fred Hutchinson Cancer Research Cen-
ter, University of Washington, Children’s Hospital
156 F. Baron et al.and Regional Medical Center, and Veterans Admin-
istration Medical Center, all in Seattle, WA, USA;
Stanford University, Palo Alto, CA, USA; City of
Hope National Medical Center, Duarte, CA, USA;
University of Leipzig, Germany; University of Colo-
rado, Denver, CO, USA; University of Torino, Italy;
University of Arizona, Tucson, AZ, USA; Baylor Uni-
versity, Dallas, TX, USA; University of Utah, Salt
Lake City, UT, USA; Oregon Health Sciences Univer-
sity, Portland, OR, USA; and, more recently, the
Medical College of Wisconsin, Milwaukee, WI,
USA; and Emory University, Atlanta, GA, USA. The
transplant regimen was remarkably well tolerated,
with the majority of patients receiving their trans-
plants in the outpatient setting.12,16,17Mixed chimerism after allogeneic HCT
following myeloablative conditioning
The term ‘‘chimerism’’ has referred to the pres-
ence of lympho-hematopoietic cells of donor origin
after an allogeneic HCT,18 and ‘‘full or complete
chimerism’’ has been defined as complete replace-
ment of host by donor lympho-hematopoiesis. For
practical reason, mixed chimerism was defined as
the detection of 5–95% cells of donor origin in
hematopoietic tissues, which approximately de-
fined the sensitivity of routinely used assays for
quantifying chimerism.
Mixed chimerism was first observed in patients
with advanced acute leukemia conditioned with
cyclophosphamide alone.19 In patients with aplas-
tic anemia conditioned with high doses of cyclo-
phosphamide with or without anti-thymocyte
globulin (ATG), mixed host/donor chimerism was
found in a substantial proportion of patients, and
this was associated with higher risk of graft rejec-
tion and, in the patients with sustained engraft-
ment, a lower risk of acute GVHD.20,21 Branch
et al.22 and Petz et al.23 reported mixed chimerism
in some patients with hematologic malignancies
transplanted with unmodified marrow grafts after
myeloablative conditioning. In these studies, the
presence of mixed chimerism did not predict subse-
quent disease relapse. However, Mackinnon et al.24
showed that minimal residual disease was more
common in chronic myeloid leukemia (CML) pa-
tients with mixed chimerism, and Huss et al.21 re-
ported that the presence of mixed chimerism
after day 100 was associated with increased re-
lapse risks in CML patients. In addition, mixed chi-
merism has been found frequently in patients who
received T-cell-depleted grafts after myeloabla-
tive conditioning,25 indirectly implying that the
recipients’ lympho-hematopoiesis was eradicatednot only by the conditioning regimens but also by
donor T cells.Methods for chimerism assessment
Several methods have been employed to determine
the degree of donor engraftment after allogeneic
HCT, including conventional and molecular cytoge-
netics (for sex mismatched donor-recipient pairs or
for patients with diseases that carry cytogenetic
abnormalities), immunoglobulin allotypes, eryth-
roid cell antigens, leukocyte isoenzymes, fluores-
cence in situ hybridization (FISH), and variable
number tandem repeat (VNTR) polymorphism anal-
yses (Table 2).18 As for the latter, certain core DNA
sequences are tandemly dispersed and repeated
throughout the genome, and the number of the
tandem repeats of the core sequences can vary be-
tween individuals. Repeats can be composed of
‘‘microsatellite’’ (also called short tandem repeats
or STR) sequences of 2–8 bp in length and repeated
up to 100 times,26,27 or of ‘‘minisatellites’’ se-
quences of 8–50 bp in length.28,29 These repeated
core sequences within a locus are characterized
by extensive polymorphism and Mendelian codomi-
nant inheritance.30,31 Polymorphic microsatellite
and minisatellite markers have advantages over
techniques that detect sex chromosomes in that
they can be used for virtually all donor-recipient
pairs and, when used in combination with DNA
amplification by polymerase chain reaction (PCR)
techniques, only small numbers of cells are re-
quired for the test. As a result, microsatellites
and minisatellites have been used extensively as
markers of engraftment and for evaluation of the
degree of chimerism in marrow transplantation in
dogs and humans.32–34 For quantification, PCR
products have been electrophoresed on an agarose
gel, hybridized with 32P-labeled probes, autoradio-
graphed and quantified by phosphor imaging (Fig.
1) or PCR was carried out with fluorescently labe-
led primers and the PCR product visualized using
the ABI 310 sequencer (Applied Biosystems, Foster
City, CA). Depending on fragment length and effi-
ciency of amplification, the sensitivity of these as-
says is between 0.1% and 5%.18,35
Short insertion/deletion polymorphisms detect-
able by quantitative real-time PCR have been intro-
duced as alternatives to VNTR or STR markers for
monitoring chimerism levels after HCT.36 Single-
nucleotide polymorphisms (SNPs) that occur on
average at every 1.3 kb in the human genome are
thought to be the most common type of genetic
variation, and the use of a multiplex microarray-
Table 2 Methods for determining chimerism.









Erythrocyte antigens53 75–80 0.1–0.5 Modera  Studies limited to the
erythroid lineage
Isoenzymes53 95 10–30 Modera  Low sensitivity
 Technical difficulty
Conventional cytogenetics53 50 10–20 Low  Low sensitivity
 Low accuracy
 Studies limited to cells
in metaphase
FISH53 50 1–2 High  Only available for sex-mismatch
HCT (or when an informative
autosomal marker is present)
 Age-association loss of the Y
chromosome in cells from older male
 Y chromosome loss in tumor cells
RFLP53 97 10–20 Modera  Technical difficulty
 High DNA requirement
 Radioactivity
VNTR/STR53 90–100 5–10 Low  Low quantitative accuracy
VNTR/STR with phosphorimaging54 90–100 0.1–1 Modera  Radioactivity
Multiplex STR amplification and fluorescence detection55 90–100 1–5 High –
Real-time PCR STR amplification56 90–100 0.1–1 High –














































Figure 1 Engraftment kinetics in a patient receiving an allogeneic transplant after a nonmyeloablative conditioning
regimen of Fludarabine and 2 Gy TBI for a metastatic renal cell carcinoma. Phosphor image analyses of the donor-
specific bands and host-specific bands were used to quantify the percentage of donor cells. Cells were separated using
anti CD3 FITC, anti-CD3 TC, anti-CD4 PE, anti-CD8 FITC, anti-CD14 TC, anti-CD56 PE and anti-CD45-labeled monoclonal
antibodies. R, recipient; D, donor; CD3+, CD3+ T cells; CD4+, CD4+ T cells; CD8+, CD8+ T cells; Mono, mononuclear cells;
NK, NK cells; Gran, granulocytes.
158 F. Baron et al.based minisequencing system screening 51 SNPs
was recently shown to provide accurate chimerism
quantification.Figure 2 Schedule of study evaluating engraftment
kinetics in 120 patients receiving allogeneic HCT follow-
ing nonmyeloablative conditioning. TBI, total body irra-
diation; MMF, mycophenolate mofetil; CSP,
cyclosporine; G-PBMC, G-CSF-mobilized peripheral blood
mononuclear cells; BM, bone marrow.Engraftment after nonmyeloablative or
reduced-intensity conditioning regimens
Kinetics of engraftment
With the exception of cyclophosphamide-condi-
tioned patients with aplastic anemia,20 engraft-
ment after nonmyeloablative conditioning
regimen was first analyzed by Childs et al.14 in 15
patients conditioned with cyclophosphamide and
fludarabine and given postgrafting immunosuppres-
sion with CSP. The patterns of engraftment varied
considerably but most often full donor chimerism
was achieved earlier in T cells than in granulocytes,
and the achievement of full donor T-cell chimerism
preceded acute GVHD and anti-tumor responses.
The kinetics of B-cell recovery were distinct from
those of myeloid and T-cell lineages, while natural
killer (NK) cell chimerism was closely correlated
with T-cell chimerism.
Ueno et al.37 studied chimerism evolution in 23
patients with metastatic tumors transplanted after
a reduced-intensity conditioning regimen consist-
ing of fludarabine and melphalan. Postgrafting
immunosuppression included tacrolimus and short
methotrexate. All patients showed 100% T-cell
and granulocyte chimerisms on days 30 and 100
after the transplant.
Dey et al.38 analyzed engraftment kinetics in 42
patients with advanced hematologic malignancies
receiving allogeneic HCT after a regimen consisting
of cyclophosphamide, anti-thymocyte globulin andthymic irradiation (the latter was given only to
those patients who had not received previous
mediastinal irradiation). Postgrafting immunosup-
pression consisted of a short course of CSP. On
day 30, median T-cell chimerism was 50% (range,
1–95%). Nineteen evaluable patients subsequently
achieved full donor T-cell chimerism, and 14 re-
jected their transplant by day 100 after HCT.
We analyzed the kinetics of donor engraftment
in various peripheral blood cell subpopulations
and their relation to HCT outcomes in a cohort of
120 patients given grafts from HLA-matched re-
lated or unrelated donors after conditioning con-
sisting of 2 Gy TBI±fludarabine, 30 mg/m2/day.
Postgrafting immunosuppression included MMF plus
CSP39 (Fig. 2). While most patients rapidly devel-
oped high degrees of donor engraftment, they re-
mained mixed donor/host chimeras for up to 6
months after HCT (Fig. 3). Generally, donor T-cell
Figure 3 Kinetics of engraftment after HCT with a
nonmyeloablative conditioning consisting of 2 Gy TBI
with or without fludarabine 30 mg/m2/day·3 days.
Median percentages of donor chimerism among periph-
eral blood cell subsets in HLA-matched related G-CSF
mobilized peripheral blood mononuclear cell recipients
(n=85).
Kinetics of engraftment following allogeneic hematopoietic cell transplantation 159chimerism lagged behind myeloid chimerism. Do-
nor T-cell chimerism on day 14 and 28 after HCT
correlated closely with both donor CD4+ (R=0.94)
and CD8+ T-cell subset (R=0.90) chimerism levels.
Correlations between donor T-cell content and
those among granulocytes (R=0.37), NK cells
(R=0.66) and monocytes (R=0.56) were weaker
at the same time points.
Associations between transplant variables
and chimerism levels
In addition to the intensity of the conditioning reg-
imen, several other variables have been associated
with chimerism levels after allogeneic HCT. These
variables either influenced the recipients’ immune
competence, thereby altering host-versus-graft
reactions, or the donor T-cells and, therewith,
graft-versus-host reactions.Variables affecting host-versus-graft
reactions
Previous chemotherapy
Several reports have shown relationships between
previous chemotherapy exposure and chimerism
levels. Valcarcel et al.40 studied 68 patients trans-
planted after conditioning with fludarabine (30
mg/m2 on days 8 to 4) and melphalan (70 mg/
m2 on days 3 and 2) in patients with lymphoid
malignancies or fludarabine (30 mg/m2 on days
9 to 5) and busulfan (total 10 mg/kg) in patients
with myeloid malignancies. GVHD prophylaxis con-
sisted of CSP and a short course of methotrexate
(MTX). In multivariate analysis, having receivedmore than two lines of chemotherapy pretrans-
plant was significantly associated with complete
donor chimerism on day 30 after HCT among
unfractionated nucleated peripheral blood cells.
Carvallo et al.41 analyzed pre-transplant varia-
bles affecting chimerism levels in 36 patients with
metastatic solid tumors conditioned with fludara-
bine/busulfan. Postgrafting immunosuppression
consisted of CSP alone or CSP combined with either
MMF or MTX. At day 30, median T-cell and granulo-
cyte chimerism levels were 98% and 76%, respec-
tively, in patients who had prior chemotherapy
versus 88% (p=0.008) and 26% (p<0.0001), respec-
tively, in patients who had not.
In our study, a univariate analysis of data from
patients who had received intensive chemotherapy
before HCT showed higher donor T-cell, granulo-
cyte, and monocyte chimerism levels (p=0.002,
0.002 and 0.01, respectively), compared to those
who did not.39 There was also a trend towards
higher donor NK cell chimerism (p=0.10). In multi-
variate analysis, intensive chemotherapy before
HCT was associated with higher T-cell (p=0.002,
average 21% increase compared to no chemother-
apy) and monocyte (p=0.04, average 15% increase
compared to no chemotherapy) chimerism levels.Hematologic disease category
We also analyzed the impact of underlying hemato-
logic diseases on engraftment kinetics. Patients
with MDS and CML had lower levels of T-cell chim-
erisms than patients with AML or with lymphoid
malignancies (p=0.03).39 After adjusting for inten-
sive previous chemotherapy, the impact on disease
category on T-cell chimerism levels was no longer
significant.Variables affecting graft-versus-host
reactions
Stem cell source/graft composition
Patients who received marrow as stem cell source
had lower percentages of donor T-cell chimerism
(p=0.002) and a trend to lower donor NK-cell chi-
merism (p=0.10) than patients who received G-
CSF-mobilized peripheral blood mononuclear cells
(G-PBMC) (Fig. 4).
Carvallo et al. found that CD34+ graft content
positively correlated with the degree of donor
myeloid chimerism, but failed to establish a corre-
lation between graft composition and donor T-cell
chimerism levels.
Baron et al. analyzed T-cell chimerism in 35 pa-
tients conditioned with TBI (2 Gy) alone (N=15),
TBI (2 Gy) and fludarabine (N=13), or fludarabine
Figure 5 Kinetics of donor T-cell engraftment in
patients receiving unmanipulated (n=18) or CD34-
selected (n=6) G-CSF mobilized peripheral blood
mononuclear cells (G-PBMC) as stem cell sources after
nonmyeloablative regimens consisting of TBI alone
(n=10), TBI+fludarabine (n=10) or cyclophosphamide
plus fludarabine (n=4). Adapted from Baron F, Schaaf-
Lafontaine N, Humblet-Baron S, et al. T-cell reconstitu-
tion after unmanipulated, CD8-depleted or CD34-selected
nonmyeloablative peripheral blood stem-cell transplan-
tation. Transplantation 2003;76:1705–13 [reference
42]. Used with permission.
Figure 4 Kinetics of donor T-cell engraftment in
patients receiving G-CSF mobilized peripheral blood
mononuclear cells (G-PBMC, n=110) or bone marrow
(marrow, n=10) as stem cell sources.
160 F. Baron et al.and cyclophosphamide (N=7). Patients received
either unmanipulated- (N=18), CD8-depleted-
(N=11) or CD34-selected-G-PBMC (N=6). Postgraft-
ing immunosuppression included MMF and CSP.
Median donor T-cell contributions on days 28, 60,
100, 180 and 365 in recipients of unmanipulated
G-PBMC were 75%, 85%, 87%, 90% and 100%, respec-
tively. Evolution of donor T-cell chimerism did not
differ significantly between recipients of unmanip-
ulated versus CD8-depleted G-PBMC while CD34
selection resulted in significantly decreased donor
T-cell chimerism42 (Fig. 5).
We also found significant correlations between
graft contents and levels of donor chimerisms.39
Higher T-cell (p=0.003), NK cell (p=0.03) and
monocyte (p=0.0002) contents in the graft were
associated with higher T-cell donor chimerisms,
while higher CD34+ cell (p=0.002) and monocyte
(p=0.04) contents resulted in higher monocyte do-
nor chimerism. In multivariate analysis, higher
numbers of monocytes in the graft (p=0.005,
modeled as a continuous linear variable) were asso-
ciated with increasing donor T-cell chimerism.
Donor type
We found no differences in chimerism levels among
patients who received HLA-matched related com-
pared to unrelated G-PBMC.39
Associations between chimerism levels and
HCT outcomes after reduced-intensity or
nonmyeloablative conditioning
Graft rejection
An increased incidence of graft rejection in aplas-
tic anemia patients with mixed donor/host chi-
merism after conditioning with cyclophosphamidewas first reported in 1986.20 Few studies to date
have analyzed the impact of lineage-specific
chimerism levels on graft rejection. Bornhauser
et al.43 suggested that fludarabine/busulfan-
conditioned patients with NK-cell donor chimerism
levels below 75% on days 10–30 after HCT were
more likely to have graft failure than those with
more than 75% (p=0.03). However, NK-cell chi-
merism levels were available in only 10 patients.
Matthes-Martin et al.44 showed that day 28 T-cell
(p=0.001) and NK-cell (p<0.0001) chimerism lev-
els were strongly correlated with late graft rejec-
tion in pediatric patients conditioned with a
reduced-intensity regimen. In contrast, granulo-
cyte/monocyte chimerism was less reliable in pre-
dicting graft rejection.
In our study, both day-14 NK- and T-cell chimer-
ism levels <50%were associatedwith significantly in-
creased risks of subsequent graft rejection (p=0.01
and p=0.02, respectively, after adjusting for donor
type (related versus unrelated)) (Table 3).39
Graft-versus-host disease
A decreased incidence of acute GVHD in patients
with sustained engraftment and mixed donor/host
chimerism was first reported in aplastic anemia pa-
tients conditioned with cyclophosphamide.20 More
recently, Childs et al.14 reported that achievement
of complete donor T-cell chimerism always pre-
ceded grade 2–4 acute GVHD. However, Mattson
Table 3 Association between day-14 donor chimerism levels and graft rejection.
% donor chimerismb,c on day 14 % of patients with rejection (# pts at risk)
T cells NK cells Granulocytes
0–50 25 (n=32) 33 (n=18) 10 (n=81)
51–75 2.5 (n=40) 5 (n=19) 0 (n=4)
76–90 0 (n=22) 0 (n=35) 0 (n=6)
91–100 0 (n=6) 0 (n=14) 0 (n=5)
p valuea p=0.02 p=0.01 p=0.05
a p values obtained trend test from logistic regression model after adjusting for presence of an unrelated donor.
b Day-14 T-cell, NK-cell, monocyte and granulocyte chimerism levels were available for 100, 86 and 96 patients, respectively.
c Percent donor chimerism as a categorical variable.
Kinetics of engraftment following allogeneic hematopoietic cell transplantation 161et al. found that 90% of their patients (conditioned
with four nonmyeloablative regimens, including
fludarabine, busulfan, TBI, cyclophosphamide and
ATG) had mixed donor/host T-cell chimerism at
the onset of acute GVHD.
Petersen et al.45 proposed that donor CD8+ T-
cell count above the median (0.043·106 cells/ll)
on day 14 after HCT predicted the risk of subse-
quent development of grade 2–4 acute GVHD.
However, only 24 patients were included in that
study.
We showed that, with increasing levels of donor
T-cell chimerisms on day 28, the probability of sub-
sequent grade 2–4 acute GVHD increased. The risk
of subsequent development of acute GVHD was 27%
in patients with T-cell chimerism levels of 6 50%,
but was 75% in patients with >90% T-cell chimerism
levels (p=0.02 after adjusting for donor type). As
observed by Mattson et al., most patients with
grades 2 and 3–4 acute GVHD were mixed donor/
host chimeras at onset of GVHD.Graft-versus-tumor effect/relapse
Two recent reports suggested a relationship be-
tween chimerism levels and disease responses. Chi-
lds et al. reported that achievement of 100% donor
T-cell engraftment always preceded anti-tumor re-
sponses. Perez-Simon et al. found a trend for a
higher relapse risk in patients with mixed T-cell
chimerism as compared to patients with complete
donor chimerism after conditioning with fludara-
bine/melphalan or fludarabine/busulfan.
In our study, 93 of 120 patients had measurable
malignant disease before transplantation, and 41
of the 93 (44%) achieved complete remissions 199
(range, 28–963) days after HCT. At the time of
achievement of complete remissions, 19 of the 41
patients showed mixed donor/host T-cell chimer-
ism and 22 had complete donor T-cell chimerism.
Neither day 28 T-cell nor NK-cell chimerism levels
were significantly associated with disease re-sponses, although there was a suggestion that pa-
tients with T-cell chimerism levels <50% were at
higher risk of failing to achieve complete remis-
sions (20% versus 47%, not significant).
Progression-free survival
Keil et al.46found an improved progression-free
survival in patients with >90% donor T-cell chimer-
ism compared to those with <90% (p<0.002) after
conditioning with 2 Gy TBI plus fludarabine.
In our study, there were no correlations between
early cell subset chimerism levels and progression-
free survival. However, when chimerism data from
days 14–100 were combined, higher donor NK cell
chimerism levels were associated with statistically
significantly improved progression-free survival [HR
0.79, 95% CI (0.64–0.96), p=0.02].Summary
Engraftment kinetics after nonmyeloablative or re-
duced-intensity conditioning depend on the inten-
sity of pretransplant chemotherapy, the intensity
of the conditioning regimens, the graft composi-
tion, and whether grafts have been depleted of T
cells. Monitoring mixed chimerism among periph-
eral blood subpopulation early after transplant
identified patients at risk for graft rejection, acute
GVHD, and death/relapse, and this knowledge
might allow early intervention with immunosup-
pressive drugs or DLI aimed at obviating these
complications.Practice points
 Kinetics of donor engraftment are different
among T cells, NK cells, granulocytes and
monocytes.
162 F. Baron et al. Patients given intensive preceding therapy
have higher granulocyte, T-cell and monocyte
donor chimerism levels.
 G-PBMC as a stem cell source is associated
with increased T-cell donor chimerism levels.
 Day-14 T- and NK-cell chimerism levels pre-
dicted patients at risk for subsequent graft
rejection.
 Day-28 T-cell chimerism levels predicted
patients at risk for subsequent GVHD.Research agenda
 Engraftment kinetics of naive and memory T
cells.
 Impact of CD4 and CD8 T-cell chimerism on
subsequent risks of rejection/GVHD.
 Impact of chimerism levels on progression-
free survival in a large group of patients with
similar diseases.Acknowledgement
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